Skip to main content

Target prediction, QSAR and conformal prediction


https://jcheminf.biomedcentral.com/articles/10.1186/s13321-018-0325-4 

You know that in the ChEMBL group, we love to play with the data we collect!! Back in April 2014, we started to work on a target prediction tool.  Wow! This was almost 5 years ago! Since then, we have continued to update the tool for each new ChEMBL release, providing you with the actual models and the result of the prediction on the ChEMBL website for the drug molecules. The good news is that these target predictions are not dead and a successor is on its way!

First, we would like to introduce you some closely related work. You may have heard about conformal prediction (CP). If not, it is a machine learning framework developed to associate confidence to predictions. I personally consider this as a requirement for decision making. Basically, you train a model as you would do in QSAR but then you first predict a so-called calibration set, for which you know the actual values. For each of these observations you obtain two probabilities: one for the active and one for the inactive class (in a typical classification scheme). Now that you have this information, each time you predict a new compound you compare its probabilities to those of the calibration set (the non-conformity scores as they are called) and you derived p-values for each class. Based on your predefined significance level, the compound can be assigned in different categories: only active or only inactive, but also both active and inactive or none of them. I am sure you can start seeing here the added value of CP!

Here I have briefly detailed how it works for classification models but CP can also be applied to regression models. If you want to know more about conformal prediction, I recommend you to read this book and also this very nice example of the application in drug discovery. Having learnt how to build conformal predictors, we were intrigued to know how well they perform against traditional QSAR models with our ChEMBL data!

With this in mind, we decided to build a panel of models using a substantial data set from ChEMBL. With our new protocol, we were able to build models for 788 targets (550 of them human targets). For the descriptors we used RDKit Morgan fingerprint (2048 bits and radius 2) and 6 physicochemical descriptors. For the machine learning part we used the good old Random Forests as implemented in Scikit-learn version 0.19. For the QSAR models, this is all that is needed, but for CP you need a framework and this was provided by the very nice library provided by Henrik Linusson.

The next part consisted of training the models and checking their internal performance, but we went a bit further and decided that with our models trained on ChEMBL_23 data, it would be interesting to see how they perform with new data in ChEMBL_24 in a so-called temporal validation. All the details, results and conclusion are presented in the recently accepted article!
Image result for right wrong decision

The dataset for each target is already available here and you can find the models ready to use there.

Feel free to take a look and to share your opinion in the comments.

Now, you remember that I started this post mentioning our good old target predictors. So does it mean a new generation of ChEMBL models using conformal prediction is ready to be launched for our users? Well, unfortunately not yet, but stay tuned!

Comments

Popular posts from this blog

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

Accessing SureChEMBL data in bulk

It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and  here for a reminder of SureChEMBL is and what it does.  This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for  local (behind the

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

New Drug Approvals - Pt. XVII - Telavancin (Vibativ)

The latest new drug approval, on 11th September 2009 was Telavancin - which was approved for the treatment of adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria , including Staphylococcus aureus , both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains. Telavancin is also active against Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus group (includes S. anginosus, S. intermedius and S. constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates only). Telavancin is a semisynthetic derivative of Vancomycin. Vancomycin itself is a natural product drug, isolated originally from soil samples in Borneo, and is produced by controlled fermentation of Amycolatopsis orientalis - a member of the Actinobacteria . Telavancin has a dual mechanism of action, firstly it inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptid